|
Re: Resverlogix Reports Filing of New Intellectual Property - question
|
3
|
Resverlogix Corp.
|
Nov 02, 2020 12:49PM
|
|
BETonRENAL
|
3
|
Resverlogix Corp.
|
Nov 16, 2020 09:50PM
|
|
Re: COVID trial now in CTD
|
3
|
Resverlogix Corp.
|
May 15, 2021 12:23PM
|
|
Baricitinib restrains the immune dysregulation in COVID 19 patients
|
3
|
Resverlogix Corp.
|
Jun 30, 2020 06:59PM
|
|
New study in the Lancet regarding COVID 19 and blood clotting
|
3
|
Resverlogix Corp.
|
Jun 30, 2020 07:09PM
|
|
Re: BETonMACE paper just published
|
3
|
Resverlogix Corp.
|
Mar 27, 2020 01:13PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call ... Bear
|
3
|
Resverlogix Corp.
|
Jun 07, 2020 11:12AM
|
|
Re: Resverlogix Announces Corporate Update Conference Call ... Bear
|
3
|
Resverlogix Corp.
|
Jun 07, 2020 11:34AM
|
|
PartnerS
|
3
|
Resverlogix Corp.
|
Jun 10, 2020 11:12AM
|
|
March Presentation
|
3
|
BIOASIS TECHNOLOGIES INC
|
Mar 24, 2021 01:02PM
|
|
Re: Lower LDL-C and Increased Type 2 Diabetes Risk
|
3
|
Resverlogix Corp.
|
Jun 03, 2020 09:59PM
|
|
Re: Proactive Article - new presentation on website
|
3
|
BIOASIS TECHNOLOGIES INC
|
Sep 23, 2020 08:37AM
|
|
Warrants
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 20, 2020 12:37PM
|
|
Re: Cytokine storm hypothesis takes a hit with the latest IL-6 targeted therapies
|
3
|
Resverlogix Corp.
|
Apr 27, 2020 01:10PM
|
|
Farxiga (SGLT2i) approved for heart failure
|
3
|
Resverlogix Corp.
|
May 06, 2020 08:53AM
|
|
Re: Report of exempt distribution
|
3
|
Resverlogix Corp.
|
Nov 10, 2020 11:10PM
|
|
BIO - Europe Digital - 2020
|
2
|
BIOASIS TECHNOLOGIES INC
|
Sep 21, 2020 02:41PM
|
|
Eastern Capital - Expiration of warrants
|
2
|
Resverlogix Corp.
|
Jul 23, 2020 06:11PM
|
|
Re: New Presentation
|
2
|
BIOASIS TECHNOLOGIES INC
|
Nov 23, 2020 07:03PM
|
|
RVX Provides Update Regarding Extension if its Filing Calendar
|
2
|
Resverlogix Corp.
|
Aug 28, 2020 07:11PM
|
